Cargando…

Clinical experience in the management of patients with Graves' orbitopathy treated according to the novel protocol of glucocorticoid therapy designed in the Department of Endocrinology, Metabolism and Internal Medicine of Poznan University of Medical Sciences

Detalles Bibliográficos
Autores principales:	Sowiński, Jerzy, Sawicka, Nadia, Skiba, Agnieszka, Ruchała, Marek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618020/ http://dx.doi.org/10.1186/1756-6614-6-S2-A54

Ejemplares similares

IgG4 as a Biomarker in Graves' Orbitopathy
por: Olejarz, Michał, et al.
Publicado: (2021)

Evaluation of IL-29 in Euthyroid Patients with Graves' Orbitopathy: A Preliminary Study
por: Falkowski, Bogusz, et al.
Publicado: (2020)

High IgG4 serum concentration is associated with active Graves orbitopathy
por: Olejarz, Michał, et al.
Publicado: (2023)

What is the best therapeutic approach if the initial glucocorticoids therapy of active Graves’ orbitopathy fails?
por: Jastrzębska, Helena
Publicado: (2013)

Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves’ opthalmopathy
por: Sawicka-Gutaj, Nadia, et al.
Publicado: (2016)

Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application
por: Längericht, Jan, et al.
Publicado: (2020)

Endoscopic intranasal orbital decompression in the course of Graves’ orbitopathy
por: Krzeski, Antoni, et al.
Publicado: (2013)

Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement
por: Bartalena, L., et al.
Publicado: (2015)

Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015)

Pharmacoeconomic aspects of the treatment of pituitary gland tumours
por: Sowiński, Jerzy, et al.
Publicado: (2013)

Asymmetric Graves’ Orbitopathy
por: Panagiotou, Grigorios, et al.
Publicado: (2020)

Network Meta-Analysis of Different Intravenous Glucocorticoid Regimes for the Treatment of Graves’ Orbitopathy
por: Jia, Jun, et al.
Publicado: (2022)

Two diagnoses become one? Rare case report of anorexia nervosa and Cushing’s syndrome
por: Sawicka, Nadia, et al.
Publicado: (2013)

The Role of the Microbiota in Graves’ Disease and Graves’ Orbitopathy
por: Hou, Jueyu, et al.
Publicado: (2021)

Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020)

Current Knowledge on Graves’ Orbitopathy
por: Gontarz-Nowak, Katarzyna, et al.
Publicado: (2020)

Orbital Signaling in Graves’ Orbitopathy
por: Draman, Mohd Shazli, et al.
Publicado: (2021)

SAT-606 Graves' Orbitopathy Treated with Kahaly's Protocol: IV High Dose Glucocorticoids
por: Patel, Bijal, et al.
Publicado: (2019)

Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021)

Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022)

Abstracts and short papers from the 5th Congress of the Polish Thyroid Association, Poznan, 3-5 September, 2015: Poznan, Poland. 3-5 September 2015
por: Wartofsky, Leonard, et al.
Publicado: (2016)

Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe Graves’ orbitopathy
por: Shen, Liyun, et al.
Publicado: (2022)

Graves′ orbitopathy: Management of difficult cases
por: Wiersinga, Wilmar M.
Publicado: (2012)

Endoscopic orbital decompression for Graves’ orbitopathy
por: Lal, Priti, et al.
Publicado: (2013)

Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2020)

Current concepts regarding Graves’ orbitopathy
por: Bartalena, Luigi, et al.
Publicado: (2022)

Update on the surgical management of Graves’ orbitopathy
por: Baeg, Joonyoung, et al.
Publicado: (2023)

Significance of HLA in the development of Graves’ orbitopathy
por: Stasiak, Magdalena, et al.
Publicado: (2023)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
por: Perros, P., et al.
Publicado: (2017)

Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression
por: Sawicka-Gutaj, Nadia, et al.
Publicado: (2015)

Glucocorticoids Directly Affect Hyaluronan Production of Orbital Fibroblasts; A Potential Pleiotropic Effect in Graves’ Orbitopathy
por: Galgoczi, Erika, et al.
Publicado: (2022)

Outcome after supracricoid laryngectomies in the material of ENT Department, Poznan University of Medical Sciences
por: Szyfter, Witold, et al.
Publicado: (2011)

Functional and Morphological Changes in the Visual Pathway in Patients with Graves’ Orbitopathy
por: Jagiełło-Korzeniowska, Agnieszka, et al.
Publicado: (2022)

Planning health care for patients with Graves’ orbitopathy
por: Sasim, Inna V., et al.
Publicado: (2008)

Surgical complications in orbital decompression for Graves' orbitopathy
por: Sellari-Franceschini, S., et al.
Publicado: (2016)

Mechanisms That Underly T Cell Immunity in Graves’ Orbitopathy
por: Fang, Sijie, et al.
Publicado: (2021)

Serum thyroglobulin is associated with orbitopathy in Graves’ disease
por: Khamisi, S., et al.
Publicado: (2021)

Correction to: Thyrotropin receptor antibodies and Graves’ orbitopathy
por: Diana, T., et al.
Publicado: (2021)

Roles of four targets in the pathogenesis of graves' orbitopathy
por: Ren, Ziqiang, et al.
Publicado: (2023)

Atypical Asymmetric Presentation of Severe Graves’ Orbitopathy
por: Gupta, Priyanka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pmcdhmrn57n03tq2l5131u9sku